Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Circulating Tumor Marker

순환 종양 표지자

  • Sung Yong Han (Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Dong Uk Kim (Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine)
  • 한성용 (부산대학교 의과대학 내과학교실, 부산대학병원 소화기내과) ;
  • 김동욱 (부산대학교 의과대학 내과학교실, 부산대학병원 소화기내과)
  • Received : 2018.11.28
  • Accepted : 2018.12.16
  • Published : 2018.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Over the past decade, circulating tumor cell have received tremendous attention as new biomarkers and basic research subjects.In recent years, research on circulating tumor DNA, exosomes and microRNAs has also been actively conducted.These circulating tumor markers have the potential to become the basis of precision medicine, such as determining the genome / immune profile, monitoring response and tolerance, and selecting therapeutic agents beyond the early diagnosis and prognosis prediction.In this article, we introduce the diagnostic methods, efficacy, meaning, and applicability of various circulating tumor markers.

지난 10 년 동안 순환하는 종양 세포는 새로운 바이오마커 및 기초 연구 대상으로 엄청난 주목을 받았다. 최근에는 순환 종양 DNA, 엑소좀 및 마이크로 RNA에 대한 연구도 활발하게 진행되고 있다. 순환 종양 표지자는 게놈 / 면역 프로필 결정, 반응 및 내성 모니터링, 조기 진단 및 예후 예측 이상의 치료제 선택과 같은 정밀 의학의 기본이 될 잠재력을 가지고 있다. 여기에서는 다양한 순환 종양 표지자의 진단 방법, 효능, 의미 및 적용 가능성을 소개하고자 한다.

Keywords

Acknowledgement

This work was supported by clinical research grant from Pusan National University Hospital in 2018.

References

  1. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146.
  2. Onuigbo WB. An index of the fate of circulating cancer cells. The Lancet 1963;282:828-831.
  3. Robinson K, McGrath R, McGrew E. Circulating cancer cells in patients with lung tumors. Surgery 1963;53:630-636.
  4. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nature Reviews Cancer 2014;14:623.
  5. Riethdorf S, Wikman H, Pantel K. Biological relevance of disseminated tumor cells in cancer patients. International journal of cancer 2008;123:1991-2006.
  6. Pantel K, Deneve E, Nocca D, et al. Circulating epithelial cells in patients with benign colon diseases. Clinical chemistry 2012;58:936-940.
  7. Grover P, Cummins A, Price T, et al. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Annals of Oncology 2014;25:1506-1516.
  8. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and molecular life sciences 2011;68:3033-3046.
  9. Andree KC, van Dalum G, Terstappen LW. Challenges in circulating tumor cell detection by the CellSearch system. Molecular oncology 2016;10:395-407.
  10. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235.
  11. Gasch C, Bauernhofer T, Pichler M, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clinical chemistry 2013;59:252-260.
  12. Mostert B, Jiang Y, Sieuwerts AM, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. International journal of cancer 2013;133:130-141.
  13. Swaminathan R, Butt AN. Circulating nucleic acids in plasma and serum. Annals of the New York Academy of Sciences 2006;1075:1-9.
  14. Heitzer E, Perakis S, Geigl JB, et al. The potential of liquid biopsies for the early detection of cancer. npj Precision Oncology 2017;1:36.
  15. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer research 2001;61:1659-1665.
  16. Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Science translational medicine 2012;4:162ra154-162ra154.
  17. Maire F, Micard S, Hammel P, et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. British journal of cancer 2002;87:551.
  18. Shoda K, Ichikawa D, Fujita Y, et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer 2017;20:126-135.
  19. Best MG, Sol N, Kooi I, et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer cell 2015;28:666-676.
  20. Tsai M-M, Wang C-S, Tsai C-Y, et al. Circulating microRNA196a/b are novel biomarkers associated with metastatic gastric cancer. European Journal of Cancer 2016;64:137-148.
  21. Qu K, Zhang X, Lin T, et al. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. Scientific reports 2017;7:1692.
  22. Hoshino A, Costa-Silva B, Shen T-L, et al. Tumour exosome integrins determine organotropic metastasis. Nature 2015;527:329.
  23. Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015;523:177.